Clinical Trials Browser

Phase 3 × INDUSTRY × Lymphoma, T-Cell × Clear all

NCT06561048 2026-03-16

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Phase 3 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Phase 3 Active not recruiting

93 enrolled 19 charts

Lymphoma, Lymphoma, T-Cell

NCT01777152 2021-11-30

ECHELON-2

Phase 3 Completed

452 enrolled 16 charts 1 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT01420679 2021-11-19

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Phase 3 Terminated

21 enrolled 8 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03349333 2019-10-01

A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL

Phase 3 Completed

85 enrolled 26 charts

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral